High materiality8/10
Rocket Pharmaceuticals upgraded to Buy from Hold at Needham
Why it may matterVerify against the original reporting
Buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
RCKT upgraded to Buy from Hold by Needham. Target is $9; current price $3.41.
- Needham upgrades RCKT to Buy; target $9; price $3.41
Key facts
- 01
Target: $9
- 02
Posted price: $3.41
- 03
Analyst firm: Needham
- 04
Analyst: Gil Blum
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.